Skip to main content

Table 1 Patient and transplantation characteristics

From: Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients

  All pts.
N = 198
HLAid
N = 133
Haplo
N = 65
p
Age, years (median, range) 32 (18–66) 32 (18–65) 31 (18–65) 0.8
Sex M/F 113/85 77/56 36/29 0.7
Number of CT lines (median, range) 2 (2–12) 2 (2–9) 4 (2–12) < 0.001
Previous HDC 170/198 (86%) 110/133 (83%) 60/65 (92%) 0.007
Disease status at transplantation
 CR 119 (60%) 82 (62%) 37 (60%)  
 PR 79 (40%) 51 (38%) 28 (40%)  
Donors     NA
 HLA sibling / 57 (43%) /  
 MUD / 76 (57%) /  
 Haplo / / 65  
Stem cell source
 PBSC 134 (60%) 114 (83%) 20 (31%) < 0.001
 BM 63 (31%) 18 (13%) 45 (69%)  
 miss 1 (9%) 1 (4%) /  
ATG prophylaxis GVHD     NA
 No 122 (62%) 57 (43%) /  
 Yes 76 (38%) 76 (57%) /  
Conditioning regimens
 NMAC 58 (29%) 2 (2%) 58 (89%) < 0.001
 RIC 101 (51%) 92 (69%) 7 (11%)  
 MAC 39 (20%) 39 (29%) /  
  1. CR complete remission, PR partial remission, MUD matched unrelated donor, BM bone marrow, PBSC peripheral blood stem cells, HDC high-dose chemotherapy
\